Document is current
Any future updates will be listed below
-
Authors
Madrer, Nimrod https://orcid.org/0000-0002-8467-5085
Vaknine-Treidel, Shani https://orcid.org/0000-0003-1424-253X
Zorbaz, Tamara
Tzur, Yonat
Bennett, Estelle R.
Drori, Paz
Suissa, Nitzan https://orcid.org/0009-0001-7646-2952
Greenberg, David S.
Lerner, Eitan https://orcid.org/0000-0002-3791-5277
Soreq, Eyal
Paldor, Iddo https://orcid.org/0000-0001-8737-5953
Soreq, Hermona https://orcid.org/0000-0002-0955-526X
-
Funding
Funding for this research was provided by:
Israel Science Foundation (1016/18, 1770/20, 3213/19, 835/23, 556/22, 556/22)
Michael J. Fox Foundation for Parkinson's Research (11183)
Ken Stein and Keter Holdings support The Leopold Sara and Norman Israel fund The Sephardi Jews aged home
ELSC and National Postdoctoral fellowships
- License Information
-
More Information
Article History
Received: 14 March 2024
Accepted: 5 March 2025
First Online: 11 April 2025
Competing interests
: H.S., N.M., E.L. and S.V.-T. have patents listed on the finding of the PD motif sequence: application 63/531,628, titled ‘Methods for detection, qualification, or monitoring of Parkinson’s disease’, and application number 63/557,661, titled ‘Angiogenin-reducing agents for treating Parkinson’s disease’. H.S. serves as the senior academic advisor to the Azrieli Fellows Program in Israel. The other authors declare no competing interests.
